Ruxolitinib 1.5% cream
Sponsors
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Milton S. Hershey Medical Center, Incyte Corporation, Icahn School of Medicine at Mount Sinai, Innovaderm Research Inc.
Conditions
Acute Skin Graft Versus Host Disease (GVHD)Discoid Lupus ErythematosusGraft Versus Host DiseaseHidradenitis SuppurativaJNS KinaseSeborrheic DermatitisTopical AdministrationVitiligo
Phase 1
Phase 2
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
TerminatedNCT03395340
Start: 2018-11-19End: 2019-01-31Updated: 2022-07-12
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
TerminatedNCT04414514
Start: 2022-10-13End: 2024-02-23Updated: 2026-04-28
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
CompletedNCT05247489
Start: 2022-05-05End: 2023-12-19Updated: 2025-02-20
Ruxolitinib in Seborrheic Dermatitis
CompletedNCT05787860
Start: 2022-11-15End: 2024-01-26Updated: 2025-05-06
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
RecruitingNCT06261021
Start: 2024-04-19End: 2026-02-28Target: 20Updated: 2025-03-24